DeCure for Female reproductive endometrioid cancer
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for female reproductive endometrioid cancer — screening already-approved drugs against its 15-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFemale reproductive endometrioid cancer maps to a 15-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for female reproductive endometrioid cancer is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibroblast growth factor 2 (FGF2) — FGF2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet idydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4OEE · 1.5 Å · ligand 1-O-methyl-2-O-sulfo-alpha-L-idopyranuronic acid (IDY). Experimental structure, not a prediction.
What the evidence adds up to
Almost 5% of women with endometrial cancer are under 40, and these patients often have well-differentiated, estrogen-dependent endometrioid tumours. Progestins may be prescribed after careful evaluation, but only for patients with grade 1 tumours, no lymphovascular space invasion, no myometrial invasion, no metastatic disease, and expression of progesterone receptors. The presence of co-existing ovarian metastases must be ruled out before ovaries are preserved. Current recommendations rest on the favourable prognosis of grade 1 minimally invasive tumours, not on randomised trial data.
Progestin-based therapy can achieve a promising outcome in young women with early stage well-differentiated endometrial cancer who have fertility desire, according to a 2020 Chinese expert consensus. After complete remission, patients are offered assisted reproductive technology or maintenance therapy depending on their immediate pregnancy plan. Hysterectomy is recommended once reproduction is finished. A 2022 review notes that 10–15% of endometrial cancer patients are young, and that for these patients surgical removal of the uterus after childbirth remains necessary.
Despite high remission rates with progestins, some patients experience hormone resistance, recurrence, or disease progression, making the treatment unsuitable for everyone. A 2025 review states that molecular classification can guide treatment and provide prognostic evaluation, but its clinical application in fertility-preserving treatment remains unclear. The same review explores combining targeted therapies with traditional treatments but offers no trial results.
What is still missing are prospective randomised trials comparing fertility-sparing regimens against standard hysterectomy in young women, validated molecular criteria to predict which patients will respond to progestins and which will relapse, and funding to test combination therapies that might overcome hormone resistance. No study provides survival data from a controlled comparison, and the long-term oncologic safety of delaying definitive surgery remains unquantified in a randomised setting.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JBRA · 2016 · 39 citations · open access
Fertility-preservation in endometrial cancer: is it safe? Review of the literature
AbstractAlmost 5% of women with endometrial cancer are under age 40, and they often have well-differentiated endometrioid estrogen-dependent tumors. Cancer survival rates have improved over the last decades so strategies to avoid or reduce the reproductive damage caused by oncologic treatment are needed. We reviewed the published literature to find evidence to answer the following questions: How should we manage women in reproductive age with endometrial cancer? How safe is fertility preservation in endometrial cancer? Can pregnancy influence endometrial cancer recurrence? What are the fertility sparing options available? Progestins may be prescribed after careful evaluation and counseling. Suitable patients should be selected using imaging methods and endometrial sampling since surgical staging will not be performed. Conservative treatment should only be offered to patients with grade 1 well-differentiated tumors, absence of lymph vascular space invasion, no evidence of myometrial invasion, metastatic disease or suspicious adnexal masses, and expression of progesterone receptors in the endometrium. The presence of co-existing ovarian metastatic of synchronous cancer should be investigated and ruled out before the decision to preserve the ovaries. The availability of Assisted Reproductive Technology (ART) has made it possible for women with endometrial cancer to give birth to a child without compromising their prognoses. Gamete, embryo or ovarian tissue cryopreservation techniques can be employed, although the latter remains experimental. Unfortunately, fertility preservation is rarely considered. Current recommendations for conservative management are based on the overall favorable prognosis of grade 1 minimally invasive tumors. Selected patients with endometrial cancer may be candidates to a safe fertility-preserving management.
Gynecology and Obstetrics Clinical Medicine · 2020 · 13 citations · open access
Chinese expert consensus on fertility-preserving treatment for young women with early stage well differentiated endometrial cancer
AbstractAbstract For young women with early stage well differentiated endometrial cancer who have fertility desire, it is import to give comprehensive assessment before initiation of conservative treatment. Progestin based therapy with regular assessment of treatment efficacy can achieve a promising outcome. After complete remission patients are suggested with assisted reproductive technology or maintenance therapy depending on their immediate pregnancy plan. Hysterectomy is recommended for patients who have finished reproduction while re-treatment for recurrent cases should be carefully informed.
Conservative management of uterine rhabdomyosarcoma
AbstractBACKGROUND: Rhabdomyosarcomas are rare, malignant tumors derived from primitive myogenic precursors and are the most common soft tissue neoplasms in children and adolescents. We used primary chemotherapy and subsequent removal of the residual polypoid mass to treat an adolescent female with uterine rhabdomyosarcoma. CASE: A 15-year-old white adolescent who presented with a polypoid uterine rhabdomyosarcoma was treated with vincristine, etopside, and ifosfamide, after which the residual polypoid mass was removed. CONCLUSION: Treating adolescent females with a polypoid uterine rhabdomyosarcoma with primary chemotherapy followed by removal of the residual mass preserves reproductive function and should be considered.
Frontiers in Oncology · 2024 · 4 citations · open access
Progestin-based pharmacotherapy in fertility preservation in early endometrial cancer
AbstractEndometrial cancer is a common tumor of the female reproductive system. In recent years, as the age of onset of the disease has gradually become younger, this has caused distress to some young patients with reproductive needs, and the active search for methods of preserving reproductive function has gradually attracted attention. In this paper, we will systematize the current status of progestin-based pharmacotherapy in combination with other drug therapies in the conservative management of early-stage endometrial cancer. With the expectation of providing a reference for the treatment of early stage endometrial cancer patients in China and for the in-depth development of related research in this field.
Gynecology and Obstetrics Clinical Medicine · 2022 · 1 citations · open access
Reproductive advance of fertility preservation in patients with early endometrial carcinoma or endometrial atypical hyperplasia
AbstractAbstract Endometrial cancer (EC) is the fourth common cancer in women worldwide with its incidence rising each year. 10%–15% young patients are diagnosed of EC. For patients of childbearing age with early endometrial cancer or atypical hyperplasia, it is necessary to consider surgical removal of uterus after they have given birth. It is a big challenge for reproductive doctors and oncologists to help such patients get pregnant safely as soon as possible. In this article, we will review the latest progress in conservative treatment and candidates for fertility preservation, application of molecular detection, the fertility outcome and follow-up treatment which aims to stimulate more thinking.
Archives of Obstetrics and Gynaecology · 2025 · 0 citations · open access
Research Progress of Molecular Classification Guiding Targeted Therapy Combined with Fertility-Preserving Treatment for Endometrial Cancer
AbstractIn recent years, the incidence of endometrial cancer has continued to increase and tends to be younger. An increasing number of young patients wish to preserve reproductive function during treatment. Although progestin therapy has a high remission rate, some patients experience hormone resistance, recurrence, or even disease progression, making this traditional treatment unsuitable for everyone. Molecular classification can effectively guide treatment and provide prognostic evaluations for endometrial cancer, but its clinical application in fertility-preserving treatment remains unclear. This article will review the role of molecular classification in endometrial cancer care and explores the potential value of combining targeted therapies with traditional treatments. The goal is to provide new strategies and insights for fertility-preserving treatment and management of endometrial cancer in the era of precision medicine.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
